A Study to Evaluate the Efficacy and Safety of SHR-2004 Injection in Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery

Prior treatment

• Have used any drugs prohibited other than investigational drugs within 7 days before screening or plan to use during the study;
• Those who have participated in any drug intervention clinical trial within 1 month before screening, or those who are within 5 half-lives of the investigational drug at the time of screening, Whichever is longer;
• Those who are expected to use plantar vein pumps, intermittent pneumatic compression devices, electronic or mechanical muscle stimulators after surgery;

Other illness

• A history that may increase the risk of bleeding;
• A history of VTE in the past or during screening, or a disease that increases thrombosis tendency such as protein C deficiency;
• Patients with atrial fibrillation requiring anticoagulant treatment or the use of artificial heart valves during screening;
• Acute coronary syndrome within 3 months;
• Poorly controlled hypertension before screening, and uncontrolled hypertension within 6 months severe cardiac arrhythmia;
• Have had a history of adverse reactions or allergies related to rivaroxaban or enoxaparin, such as heparin-induced thrombocytopenia;

Lab values

• Any laboratory test indicator during screening or baseline does not meet the standards in the exclusion criteria;

Other

• The primary site of the tumor is not the ovary or there is brain metastasis;
• Those who are expected to use postoperative neuraxial analgesia;
• Other circumstances in which the researcher believes that the subject is not suitable to participate in this trial.

• Aged ≥ 18 years old on the day of signing the informed consent form;
• Diagnosed as stage III-IV or recurrent ovarian cancer;
• Have surgical indications and no contraindications to surgery, and voluntarily undergo laparotomy or laparoscopic surgery to treat ovarian cancer;
• Understand the research procedures and methods, voluntarily participate in this trial, and sign the written informed consent form.